CBL-0137 is under clinical development by Incuron and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect CBL-0137’s likelihood of approval (LoA) and phase transition for Melanoma took place on 07 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CBL-0137 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
CBL-0137 (CBLC-137) is under development for the treatment of melanoma (second line therapy), sarcoma (second line therapy) and resistant or refractory advanced solid cancers, osteosarcoma and pediatric diffuse intrinsic pontine glioma. It is administered through oral, intraarterial, and intravenous routes. The drug candidate is a carbazole-derived compound. It is developed based on Curaxin technology.
It was also under development for the treatment of pancreatic ductal adenocarcinoma, colon adenocarcinoma, renal cell carcinoma, human non-small cell lung cancer, mammary gland adenocarcinoma, pancreatic cancer, head and neck cancer, prostate cancer, melanoma, glioblastoma, neuroblastoma, glioblastoma multiforme (second line therapy), hematological malignancies like diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, Hodgkin lymphoma (B -cell Hodgkin lymphoma), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (all, acute lymphoblastic leukemia), acute myelocytic leukemia (aml, acute myeloblastic leukemia), multiple myeloma (Kahler disease), B -cell non-Hodgkin lymphoma and human African trypanosomiasis.
Quick View CBL-0137 LOA Data
|Highest Development Stage|